You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA119
  • Published:  28 February 2007
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Leukaemia: Final appraisal determination - consultee and commentator comments

  • Leukaemia: FAD - consultee and commentator comments: Department of Health

  • Leukaemia: FAD - consultee and commentator comments: Royal College of Pathologists

  • Leukaemia: FAD - consultee and commentator comments: Children with leukaemia

  • Leukaemia: FAD - consultee and commentator comments: Cancer backup

  • Leukaemia: FAD - consultee and commentator comments: British committee for standards in haematology

  • Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd - MHRA update

  • Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd


This page was last updated: 30 March 2010

Back to top